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ABSTRACT
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2)
is a lipoprotein-bound enzyme that can release atherogenic isopros-
tanes from esterified phospholipids and that may be involved in
inflammation and atherosclerosis.
Objective: This study investigates the association between Lp-
PLA2 activity and coronary artery disease (CAD) in relation to
oxidative stress markers, in particular urinary 8-epi-prostaglandin
F2 (8-epi-PGF2).
Design: We conducted a case-control study in which the cross-
sectional relation between Lp-PLA2 activity, lipoproteins, and oxi-
dative stress markers was determined in 799 patients with angio-
graphically confirmed CAD and 925 healthy controls.
Results: Lp-PLA2 activity was significantly (P  0.001) higher in
CAD cases than in controls (32.9  0.46 and 29.7  0.42
nmol  mL1  min1, respectively). Both elevated Lp-PLA2 activ-
ity and urinary excretion concentrations of 8-epi-PGF2 were asso-
ciated with greater CAD risk (P for trend 0.001). Odds ratios for
the upper quartiles of Lp-PLA2 activity and 8-epi-PGF2.excretion
were 2.47 (95% CI: 1.79, 3.40) and 2.19 (1.52, 3.15), respectively,
after adjustment for sex, age, BMI, blood pressure, smoking and
alcohol consumption status, and LDL and HDL cholesterol. When
we examined the additive effect of both markers for CAD risk, the
relation between 8-epi-PGF2 and CAD was weakened above the
second quartile of Lp-PLA2 activity. Moreover, Lp-PLA2 activity
was positively correlated with urinary excretion concentrations of
8-epi-PGF2 in controls (r0.277, P0.001) and cases (r0.202,
P0.001) and with the tail moment of lymphocyte DNA (r0.213,
P 0.001) in controls.
Conclusion: This study shows an association of elevated Lp-PLA2
activity with CAD risk in relation to oxidant stress and thus supports
a proatherogenic role of Lp-PLA2. Am J Clin Nutr 2008;88:
630–7.
INTRODUCTION
The biological role of lipoprotein-associated phospholipase
A2 (Lp-PLA2) is controversial: whereas initial reports indicate an
antiatherogenic effect (1), there is growing evidence of a role for
Lp-PLA2 as a proinflammatory molecule and an independent
risk factor for coronary artery disease (CAD) (2–6). Lp-PLA2 is
a lipoprotein-bound enzyme that catalyzes the hydrolysis of ox-
idized phospholipids, generating bioactive oxidized free fatty
acids and lysophosphatidylcholine, which are potent proinflam-
matory and proatherogenic products (7). In addition, plasma
Lp-PLA2 is responsible for the release of F2-isoprostanes, the
end-products of lipid peroxidation, into the bloodstream (8).
Some studies have indicated that F2-isoprostanes are probably
the most valid in vivo markers of oxidative stress (9, 10). There
is evidence that cardiovascular risk is related, at least in part, to
greater systemic oxidative stress, and oxidative damage is known
to be involved in the pathogenesis of atherosclerosis and CAD
(11, 12), in which it is closely associated with the inflammatory
response and bioactive lipid formation. To determine the oxida-
tion status of a person, a set of oxidative markers is recom-
mended, including 1 marker each for lipid peroxidation, pro-
tein oxidation, and total antioxidative status and, ideally, 1
marker for DNA damage (13).
This case-control study was designed to determine the relation
between Lp-PLA2 activity and angiographically proven CAD. In
addition, we wanted to explore the relation between Lp-PLA2
and a variety of oxidative stress markers, in particular urinary
8-epi-prostaglandin F2 (8-epi-PGF2), to shed further light on
the pathogenic role of this emerging biomarker for CAD risk.
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SUBJECTS AND METHODS
Subjects
This study involved 1724 unrelated Korean subjects (1520
men and 204 women) aged 31–83 y. Subjects were divided into
2 subgroups: a control group of 925 persons (805 men and 120
women) with no history or clinical evidence of CAD, who were
recruited either from the Health Service Center during the course
of routine check-up visits or by advertisements briefly describing
the study design, and a case group of 799 patients (715 men and
84 women) with CAD, who were recruited from the Cardiovas-
cular Center at Yonsei University Severance Hospital (Seoul,
Korea) or National Health Insurance Corporation Ilsan Hospital
(Goyang-si, Korea).
The inclusion criteria for controls were no history or diagnosis
of atherosclerosis, vascular disease, chronic heart failure and
arrhythmias, diabetes mellitus, or cancer and no pathologic elec-
trocardiogram patterns. The inclusion criteria for CAD cases
were angiographic evidence of 50% occlusion of 1 major
coronary artery or previously confirmed myocardial infarction
according to the World Health Organization criteria for symp-
toms, enzyme elevation, or electrocardiographic changes; ab-
sence of nonatherogenic occlusion, such as osteal stenosis and
spasm; and no history or diagnosis of diabetes mellitus or any
diagnosis of thyroid or pituitary disease. Exclusion criteria in-
cluded abnormal liver or renal function (ie, serum aminotrans-
ferase activity40 IU/L and serum creatinine concentrations1.2
mg/dL); cancer (diagnosed clinically or by anamnesis); extreme
weight loss or gain over the previous 6 mo; thyroid or pituitary
disease; infection determined by medical questionnaire and com-
plete blood count; and acute or chronic inflammatory disease.
The purpose of the study was carefully explained to all par-
ticipants, and their written informed consent was obtained. The
study protocol was approved by the Institutional Review Board
of Yonsei University, and the study was carried out in accordance
with the Helsinki Declaration.
Survey method, anthropometric measurements, and
blood collection
All subjects completed a standardized questionnaire adminis-
tered by a specially trained interviewer to provide information on
lifestyle factors, current medication use, and medical history. For
CAD patients, information was also taken from the hospital med-
ical records. Briefly, subjects were categorized into current
smokers, ex-smokers, and never smokers and current alcohol
consumers, ex-consumers, or nonconsumers. Data on the fre-
quency of use of all medications, in particular the antihyperten-
sive, hypoglycemic, antidyslipidemic, and antiplatelet drugs,
were collected.
Body weight and height were measured in the morning, while
the participants were unclothed and not wearing shoes. Body
mass index (BMI; in kg/m2) was calculated. Waist and hip cir-
cumferences were measured with the use of a paper tape placed
horizontally at the umbilicus while the participants were in a
standing position after normal expiration. Blood pressure was
measured from the left arm of seated participants with the use of
an automatic blood pressure monitor (TM-2654; A&D, Tokyo,
Japan) after 20 min of rest. The average of 3 measurements was
recorded for each subject.
Venous blood specimens were collected in EDTA-treated or
plain tubes after a 12-h fast. The tubes were immediately covered
with aluminum foil and placed on ice until they arrived at the
laboratory room (within 1–3 h), where they were stored at
70 °C until they were analyzed.
Serum lipid profile and C-reactive protein concentraion
Fasting serum concentrations of total cholesterol and triglyc-
erides were measured by using commercially available kits on a
Hitachi 7150 Autoanalyzer (Hitachi Ltd, Tokyo, Japan). After
precipitation of serum chylomicron conducted with dextran sul-
fate magnesium, the concentrations of LDL and HDL cholesterol
in the supernatant fluid were measured by using an enzymatic
method. LDL cholesterol was indirectly estimated in participants
with serum triglyceride concentrations  4.52 mol/L (400 mg/
mL) by using the Friedewald formula. In participants with serum
triglyceride concentrations 4.52 mol/L, LDL cholesterol was
directly measured by using an enzymatic method on a Hitachi
7150 Autoanalyzer. Serum apolipoprotein A-I and B concentra-
tions were measured by using turbidometry at 340 nm with a
specific antiserum (Roche, Basel, Switzerland). Serum high-
sensitivity C-reactive protein (hs-CRP) concentrations were
measured with an Express plus autoanalyzer (Chiron Diagnos-
tics Co, Walpole, MA) by using a commercially available hs-
CRP Latex (II) X2 kit (Seiken Laboratories Ltd, Tokyo, Japan)
that allowed detection of CRP concentrations in the range of
0.001 to 32 mg/dL.
Lipoprotein-associated phospholipase A2 activity and
plasma oxidized LDL concentrations
Lp-PLA2 activity, also known as platelet-activating factor
(PAF)–acetylhydrolase, was measured by using a modification
of a previously described high-throughput radiometric activity
assay (4). Briefly, a micelle substrate was prepared with unla-
beled PAF and [3H]PAF (100Ci/mL, 21.5 Ci/mmol; NET 910;
PerkinElmer, Waltham, MA) in 10 mmol phosphate-buffered
saline (PBS)/L (pH 7.4), containing 2.7 mmol EDTA/L (PBS-
EDTA). The reaction mixture, containing 20 L human plasma
and 140L PBS-EDTA, was incubated at 37 °C for 15 min. The
reaction was initiated by the addition of 40 L micelle substrate
(0.05 Ci, final concentration 80 mol PAF/L) to measure the
initial Lp-PLA2 activity. The reaction was stopped by mixing by
vortex with 600 L CHCl:MeOH (2:1), and the CHCl3 and
aqueous layers were separated by centrifugation at 1500 rpm for
3 min at 4 °C. The aqueous layer (300 L) was removed and
mixed by vortex with 300L CHCl. The aqueous layer (100L)
was again removed and added to 3 mL scintillation cocktail
(Lumagel; Lumac Co, Groningen, Netherlands) in a scintillation
vial. The [3H] acetate counts were determined by using a liquid
scintillation counter (1450 Microbeta Trilux; Qallac Oy, Turku,
Finland). The raw counts were corrected for background by using
an enzyme-noncontaining blank and were expressed as nmol
degraded PAF  min1  mL1 plasma. The intraassay and inter-
assay CVs were 11.27% and 8.71%, respectively.
Plasma oxidized LDL (ox-LDL) was measured by using an
enzyme immunoassay (Mercodia, Uppsala, Sweden). The result-
ant color reaction was read at 450 nm with a Wallac Victor2
multilabel counter (Perkin Elmer Life Sciences, Turku, Finland).
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Lipid peroxidation: urinary 8-epi-prostaglandin F2and
plasma malondialdehyde
Urine was collected in polyethylene bottles containing 1%
butylated hydroxytoluene after a 12-h fast. The tubes were im-
mediately covered with aluminum foil and stored at70 °C until
they were analyzed. We measured 8-epi-prostaglandin F2 (8-
epi-PGF2) by using an enzyme immunoassay (BIOXYTECH
urinary 8-epi-PGF2 assay kit; OXIS International Inc, Portland,
OR) and the resulting color reaction was read at 650 nm by using
a Wallac Victor2 multilabel counter. Urinary creatinine was
measured by using the alkaline picrated (Jaffe) reaction. Urinary
8-epi-PGF2 concentrations were expressed as pmol/mmol cre-
atinine. Plasma malondialdehyde (MDA) was assayed by using
the fluorometric method described by Buckingham (14).
Alkaline comet assay for DNA damage
For the comet assay, 120L whole blood was mixed with 900
L PBS, and the mixture was poured gently over 150 L lym-
phocyte separation solution (Histopaque-1077; Sigma-Aldrich
Korea Ltd, Yong-In, Korea). After a 4-min centrifugation at 1450
rpm and 4 °C, lymphocytes were removed with a pipette and
transferred to another tube. DNA damage was analyzed as de-
scribed by Green et al (15).
Statistical analysis
Statistical analyses were performed with SPSS for WIN-
DOWS software (version 12.0; SPSS Inc, Chicago, IL). Differ-
ences in biomarkers between CAD cases and controls were an-
alyzed by using Student’s t test. A chi-square test was used to test
whether there was a difference in sex distribution, cigarette
smoking, alcohol consumption, and medication therapy between
CAD cases and controls. Pearson and partial correlation coeffi-
cients were used to examine the relation of Lp-PLA2 activity and
markers of oxidative stress. In addition, Bonferroni correction
for multiple testing was used with0.005 after the 11 different
laboratory variables tested were taken into account.
Plasma Lp-PLA2 activity or urinary 8-epi-PGF2 concentra-
tions were divided into quartiles according to their distribution in
the control group. Next, multiple logistic regression analysis
including CAD as a dependent variable and Lp-PLA2 activity or
urinary excretion concentration of 8-epi-PGF2 as an indepen-
dent variable was applied to estimate the independent association
of elevated Lp-PLA2 activity or urinary 8-epi-PGF2 excretion
concentration with the presence of CAD; simultaneous control
for confounding factors was exerted. Results were presented as
odds ratio (ORs) and 95% CIs estimated from the logistic regres-
sion model with initial control for sex, age, and BMI and subse-
quent further control for blood pressure, cigarette smoking, al-
cohol consumption, lipid profiles, and statin therapy. Finally, the
Lp-PLA2 activity  urinary excretion concentration of 8-epi-
PGF2 interaction for CAD risk was evaluated by using multiple
logistic regression analysis. Each OR was estimated with com-
parison of the reference group in the lowest quartiles for both
variables after adjustment for sex, age, BMI, blood pressure, and
smoking and alcohol consumption status.
We examined whether each variable presented a normal dis-
tribution before statistical testing, and then we performed loga-
rithmic transformation on the skewed variable (ie, triglycerides,
8-epi-PGF2, CRP, malondialdehyde, and ox-LDL). For descrip-
tive purposes, mean values are presented by using untransformed
and unadjusted values. Results are expressed as meanSEs, and
a 2-tailed value of P  0.05 was considered statistically signif-
icant.
RESULTS
Characteristics of cases and controls
General characteristics of 799 CAD cases and 925 controls are
shown in Table 1. Cases were significantly older and heavier and
had a larger waist-to-hip ratio than did controls, whereas there
was no significant difference between the groups in sex distri-
bution. Current smoking and alcohol consumption were more
common in the controls than in the cases. Statins, antihyperten-
sives, and antiplatelet agents were used more frequently in cases
than in controls (47.8% and 0.9%, 69% and 4.8%, and 71% and
1.2%, respectively). Consequently, systolic and diastolic blood
pressure and concentrations of total, LDL, and HDL cholesterol
were lower in cases than in controls, although cases had higher
concentrations of triglyceride. Oxidative stress and inflamma-
tion were evaluated by measurement of urinary 8-epi-PGF2,
plasma MDA, lymphocyte DNA damage, ox-LDL, and serum
hs-CRP. Compared with controls, cases had significantly higher
concentrations of urinary 8-epi-PGF2, plasma MDA, and serum
hs-CRP; significantly greater lymphocyte DNA damage; and
significantly lower concentrations of ox-LDL. Lp-PLA2 activity
was significantly higher in cases than in controls (32.9  0.46
and 29.7 0.42 nmol  mL1  min1, respectively; P 0.001)
(Table 1).
Correlation between lipoprotein-associated phospholipase
A2 activity, lipoproteins, high-sensitivity C-reactive
protein, and markers of oxidative stress
In controls, Lp-PLA2 activity was positively correlated with
urinary excretion concentrations of 8-epi-PGF2 and lympho-
ctye DNA damage (tail DNA, tail length, and tail moment) after
Bonferroni correction for multiple testing ( 0.005) (Table 2).
These associations remained significant after adjustment for age
and medication use. In cases, Lp-PLA2 activity was positively
correlated with urinary excretion concentrations of 8-epi-PGF2
after Bonferroni correction; however, Lp-PLA2 activity was not
significantly correlated with age; BMI; total, HDL, or LDL cho-
lesterol; triglyceride; MDA; ox-LDL; or CRP in either cases or
controls (Table 2).
Association of lipoprotein-associated phospholipase A2
activity and 8-epi-prostaglandin F2 concentration with
coronary artery disease
Both Lp-PLA2 activity and urinary excretion concentrations
of 8-epi-PGF2 showed a concentration-dependent association
with CAD in the logistic regression model after control for the
confounding factors in stages (Table 3). Lp-PLA2 activity in the
highest quartile (41.0 nmol  mL1  min1) was associated
witha2.14-foldriskofCAD(95%CI:1.61,2.84)comparedwiththe
lowest quartile of Lp-PLA2 activity (20.4 nmol  mL1  min1)
in a model adjusted for sex, age, and BMI (model 1). After
additional adjustment for blood pressure, smoking and alcohol
consumption status, and LDL and HDL cholesterol, the OR in-
creased to 2.47 (95% CI: 1.79, 3.40) (model 4). Further adjust-
ment for statin therapy (model 5) attenuated the risk associated
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with high Lp-PLA2 activity, although the risk remained signifi-
cantly elevated, with an OR of 1.92 (95% CI: 1.32, 2.79), in the
highest quartile compared with the lowest quartile.
The urinary excretion concentration of 8-epi-PGF2 was as-
sociated with a higher OR for CAD in the third (1012.9–1381.8
pg/mg creatinine) and top (1381.8 pg/mg creatinine) quartiles,
as compared with the lowest quartile (744.6 pg/mg creatinine):
the OR for 8-epi-PGF2 in the highest quartile was 2.19 (95% CI:
1.59, 3.0) after adjustment for sex, age, and BMI model (model
1) and 2.55 (95% CI: 1.60, 4.06) after further adjustment for
blood pressure, smoking and alcohol consumption status, lipids,
and statin therapy (model 5). However, when we also adjusted for
Lp-PLA2 activity (model 6), the OR for the highest quartile was
reduced to 1.80 (95% CI: 1.01, 2.94), and 8-epi-PGF2 concen-
trations in the highest quartile were significantly associated with
a greater CAD risk only when compared with values in the lowest
quartile.
Because the joint effect of the quartile of Lp-PLA2 activity and
the quartile of urinary 8-epi-PGF2 concentration was significant
(P 0.001 for 2 test with 15 df), the interactive effect of both
markers with respect to CAD risk was evaluated (Figure 1).
Compared with participants in the lowest categories of both
variables, participants in almost all of the other categories had
significantly greater risk of CAD; those in the lowest quartile of
Lp-PLA2 activity and the second and third quartiles of 8-epi-
PGF2 concentrations did not have greater risk. The combination
of elevated Lp-PLA2 activity and elevated 8-epi-PGF2 concen-
trations was generally more significant than was the elevation of
either one separately. Overall, the increase in CAD risk with
increasing Lp-PLA2 activity was sustained with respect to in-
creases in 8-epi-PGF2 concentrations; however, the relation
between 8-epi-PGF2 and CAD risk was weakened above the
second quartile of Lp-PLA2 activity.
DISCUSSION
To our knowledge, the present study is the first to focus on the
relation between Lp-PLA2 activity and markers of oxidative
stress and, in particular, on the association between urinary ex-
cretion of 8-epi-PGF2 and CAD. In this case-control study,
Lp-PLA2 activity and urinary 8-epi-PGF2 concentration were
higher in patients with CAD than in healthy controls, and both
elevated Lp-PLA2 activity and urinary excretion concentration
of 8-epi-PGF2 were significantly associated with the risk of
CAD, even after control for potential confounders including
HDL cholesterol, LDL cholesterol, and statin therapy. It is in-
teresting that, when the combined effect of 8-epi-PGF2 concen-
tration and Lp-PLA2 activity on CAD risk was examined, the
association between 8-epi-PGF2 concentration and CAD risk
was weakened by greater Lp-PLA2 activity. In addition, when
CAD risk for the upper quartiles of 8-epi-PGF2 was compared
with that for the lowest quartile, additional adjustment for Lp-
PLA2 activity attenuated the risk associated with elevated 8-epi-
PGF2. Our data show the confirmatory association of elevated
TABLE 1
Anthropometric and biochemical characteristics of controls and coronary artery disease (CAD) cases1
CAD cases (n 799) Controls (n 925) P2
Age (y) 56.1 0.33 55.2 0.3 0.036
Female n (%) 84 (11) 120 (13) NS
BMI (kg/m2) 25.1 0.1 24.6 0.1 0.001
Waist-to-hip ratio 0.9 0.0 0.9 0.0 0.001
Current smoker n (%) 178 (22) 256 (28) 0.009
Current drinker n (%) 432 (54) 620 (67) 0.001
Statin therapy n (%) 382 (47.8) 8 (0.9) 0.001
Antihypertensive therapy n (%) 548 (69) 44 (4.8) 0.001
Antiplatelet therapy n (%) 567 (71) 11 (1.2) 0.001
Systolic BP (mm Hg) 124.1 0.6 125.8 0.5 0.034
Diastolic BP (mm Hg) 77.7 0.3 79.8 0.4 0.001
Total cholesterol (mg/dL) 171.2 1.4 196.1 1.2 0.001
HDL cholesterol (mg/dL) 43.6 0.4 51.0 0.5 0.001
LDL cholesterol (mg/dL) 97.8 1.3 117.4 1.1 0.001
Triglyceride (mg/dL)4 141.2 2.4 132.2 2.2 0.001
8-epi-PGF2 (pg/mg creatinine)4 1332.9 29.4 1123.6 20.1 0.001
Malondialdehyde (nmol/mL)4 11.8 0.2 9.2 0.1 0.001
Lymphocyte DNA damage
Tail DNA (%) 13.1 0.3 13.0 0.3 NS
Tail length (m) 73.1 2.4 49.1 0.9 0.001
Tail moment5 13.2 0.7 7.8 0.3 0.001
Oxidized LDL (U/L)4 48.8 1.1 57.6 1.0 0.001
hs-CRP (mg/dL)4 2.2 0.2 1.2 0.1 0.001
Lp-PLA2 activity (nmol  mL1  min1) 32.9 0.5 29.7 0.4 0.001
1 BP, blood pressure; 8-epi-PGF2, 8-epi-prostaglandin F2; hs-CRP, high-sensitivity C-reactive protein; Lp-PLA2, lipoprotein-associated phospholipase
A2. Data are reported by using untransformed values.
2 Tested by Student’s t test or chi-square test (2-sided).
3 x  SE (all such values).
4 Tested by logarithmic transformation.
5 Tail moment % of DNA in the tail tail length (m).
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Lp-PLA2 activity with CAD risk, which is consistent with pre-
vious reports (2–5, 16, 17), and which sheds further light on a
proatherogenic role of Lp-PLA2 in relation to oxidant stress.
Lp-PLA2 is known to catalyze hydrolysis of the sn-2 position
of glycerophospholipids to liberate arachidonic acid, a precursor
of eicosanoids such as prostaglandins and leukotrienes (18).
Radical peroxidation of arachidonic acid results in a family of
prostaglandin F2-isomers called F2-isoprostanes (13). One such
F2-isoprostane is 8-epi-PGF2, a sensitive and independent risk
marker for coronary heart disease (19–21) that is probably re-
leased into biological fluids through a phospholipase-mediated
pathway and consequently excreted in urine. Indeed, Stafforini et
al (8) showed that the secreted form of Lp-PLA2 released F2-
isoprostanes from the sn-2 position of phosphatidylcholine with
high affinity, and Kono et al (22) recently reported that intracel-
lular type II Lp-PLA2, which shares homology with the plasma
enzyme Lp-PLA2, is involved in the metabolism of esterified
8-iso-PGF2. Moreover, plasma samples from Lp-PLA2–defi-
cient subjects do not release F2-isoprostanes from esterified pre-
cursors ex vivo (8). Our finding of a positive correlation between
Lp-PLA2 activity and urinary excretion of 8-epi-PGF2 in both
TABLE 2
Correlation coefficients between lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and lipid profiles, C-reactive protein, and oxidative stress
markers in coronary artery disease (CAD) cases and controls1
CAD cases (n 799) Controls (n 925)
r P R2 P2 r P R2 P2
Age (y) 0.015 0.667 0.025 0.450
BMI (kg/m2) 0.027 0.439 0.032 0.429 0.014 0.662 0.010 0.789
Total cholesterol (mg/dL) 0.048 0.174 0.071 0.081 0.035 0.282 0.034 0.344
HDL cholesterol (mg/dL) 0.062 0.081 0.050 0.226 0.015 0.647 0.008 0.827
LDL cholesterol (mg/dL) 0.076 0.035 0.084 0.042 0.062 0.066 0.042 0.241
Triglyceride (mg/dL)3 0.026 0.476 0.075 0.069 0.011 0.735 0.001 0.983
8-epi-PGF2 (pg/mg creatinine)3 0.202 0.0014 0.192 0.0014 0.277 0.0014 0.291 0.0014
Malondialdehyde (nmol/mL)3 0.061 0.094 0.022 0.601 0.061 0.092 0.034 0.388
Lymphocyte DNA damage
Tail DNA (%) 0.100 0.047 0.096 0.058 0.190 0.0014 0.199 0.0014
Tail length (m) 0.046 0.360 0.045 0.381 0.165 0.0014 0.161 0.005
Tail moment5 0.068 0.174 0.068 0.177 0.213 0.0014 0.220 0.0014
Oxidized LDL (U/L)3 0.018 0.690 0.040 0.490 0.046 0.226 0.063 0.137
hs-CRP (mg/dL)3 0.025 0.492 0.042 0.305 0.014 0.692 0.008 0.819
1 8-epi-PGF2, 8-epi-prostaglandin F2; hs-CRP, high-sensitivity C-reactive protein.
2 Controlled for age and medication use (antihypertensive, statin, and antiplatelet therapy).
3 Tested by logarithmic transformation.
4 Statistically significant correlation after Bonferroni correction.
5 Tail moment % of DNA in the tail tail length (m).
TABLE 3
Odds ratios (OR) of coronary artery disease associated with lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and urinary 8-epi-prostaglandin
F2 (8-epi-PGF2) excretion concentrations after various adjustments1
Cases Controls Model 12 Model 23 Model 34 Model 45 Model 56 Model 67
n n
Lp-PLA2 activity (nmol  mL1  min1)
Quartile 1 (20.4) 124 231 1.0 1.0 1.0 1.0 1.0 —
Quartile 2 (20.4–25.4) 191 231 1.54 (1.15, 2.06) 1.49 (1.10, 2.01) 1.59 (1.17, 2.18) 1.75 (1.26, 2.45) 1.18 (0.79, 1.77) —
Quartile 3 (25.4–41.0) 221 232 1.78 (1.34, 2.38) 1.78 (1.33, 2.38) 1.67 (1.23, 2.27) 1.93 (1.39, 2.68) 1.76 (1.21, 2.55) —
Quartile 4 (41.0) 263 231 2.14 (1.61, 2.84) 2.15 (1.61, 2.88) 2.12 (1.57, 2.86) 2.47 (1.79, 3.40) 1.92 (1.32, 2.79) —
P for trend 0.001 0.001 0.001 0.001 0.001
8-epi-PGF2 (pg/mg creatinine)
Quartile 1 (744.6) 160 231 1.0 1.0 1.0 1.0 1.0 1.0
Quartile 2 (744.6–1012.9) 136 232 0.89 (0.63, 1.25) 0.83 (0.58, 1.18) 0.85 (0.59, 1.22) 0.80 (0.54, 1.18) 0.76 (0.44, 1.29) 0.66 (0.38, 1.13)
Quartile 3 (1012.9–1381.8) 202 231 1.39 (1.00, 1.93) 1.43 (1.02, 2.01) 1.48 (1.05, 2.09) 1.39 (0.96, 2.01) 1.80 (1.11, 2.89) 1.45 (0.89, 2.37)
Quartile 4 (1381.8) 299 231 2.19 (1.59, 3.00) 2.20 (1.58, 3.06) 2.35 (1.67, 3.31) 2.19 (1.52, 3.15) 2.55 (1.60, 4.06) 1.80 (1.01, 2.94)
P for trend 0.001 0.001 0.001 0.001 0.001 0.001
1 Data are ORs (95% CI) for the association between the 3 upper quartiles of Lp-PLA2 activity or urinary 8-epi-PGF2 concentrations in comparison with
the bottom quartile and coronary artery disease, tested by multivariable logistic regression analysis. Quartiles are based on data from control subjects.
2 Adjusted for sex, age, and BMI.
3 Adjusted for sex, age, BMI, systolic and diastolic blood pressure, and smoking and alcohol consumption status.
4 Adjusted for sex, age, BMI, systolic and diastolic blood pressure, smoking and alcohol consumption status, and HDL cholesterol.
5 Adjusted for sex, age, BMI, systolic and diastolic blood pressure, smoking and alcohol consumption status, and HDL and LDL cholesterol.
6 Adjusted for sex, age, BMI, systolic and diastolic blood pressure, smoking and alcohol consumption status, HDL and LDL cholesterol, and statin therapy.
7 Adjusted for sex, age, BMI, systolic and diastolic blood pressure, smoking and alcohol consumption status, HDL and LDL cholesterol, statin therapy,
and Lp-PLA2 activity.
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controls and cases adds evidence to support the possibility that
this enzyme may modulate oxidant stress.
When the interactive effect between Lp-PLA2 activity and
urinary excretion of 8-epi-PGF2 on CAD risk was evaluated,
persons with Lp-PLA2 activity in the highest quartile (41.0
nmol  mL1  min1) and 8-epi-PGF2 concentrations in the
highest quartile (1381.8 pg/mg creatinine) had a CAD risk8
times greater than that in persons with Lp-PLA2 activity (20.4
nmol  mL1  min1) and 8-epi-PGF2 (744.6 pg/mg creati-
nine) in the lowest quartile (P  0.001; 95% CI: 4.50, 16.0).
Although this result has the limitation of reflecting only the
relative risk in the present population, it may suggest that ele-
vated Lp-PLA2 activity and urinary excretion concentrations of
8-epi-PGF2, along with other factors that promote inflammation
and oxidant stress, may drive the more susceptible status to
atherosclerosis in persons. In addition, we show that the elevation
of CAD risk by an increase in the urinary excretion of 8-epi-
PGF2 was attenuated by greater Lp-PLA2 activity, which sug-
gests that Lp-PLA2 may play an active role in atherogenesis,
rather than simply being a risk marker. However, because the
present study was designed as a case-control study, we are not
currently able to explain the reason for such effects.
In the present study, Lp-PLA2 activity positively correlated
with 8-epi-PGF2 and lymphocyte DNA damage in controls.
These correlations persisted after Bonferroni correction for mul-
tiple testing (0.005), even after adjustment for sex, age, BMI,
smoking and alcohol consumption status, and medication ther-
apy, all of which are known to affect concentrations of PGF2
(13, 23, 24) and degrees of DNA damage (13, 25–28) (data not
shown). Semiquantitative analysis has shown that the isopros-
tane 8-epi-PGF2 is one of the most reliable markers of oxidative
stress (19, 20, 29–31). Oxidative stress has been suggested as the
major cause of DNA damage, and greater degrees of DNA dam-
age in patients with CAD have been reported (32–34). In the
present study, we measured lymphocyte DNA damage by using
the comet assay, a sensitive and reliable determinant of oxidative
stress and DNA damage (35). The positive correlation observed
between Lp-PLA2 activity and both 8-epi-PGF2 and lympho-
cyte DNA damage suggests that persons with high Lp-PLA2
activity may have higher levels of lipid peroxidation and oxida-
tive stress and may therefore have a greater risk of CAD than do
persons with normal Lp-PLA2 activity. Such observations sup-
port the conclusion that Lp-PLA2 is proatherogenic (36).
Ox-LDL, another variable of lipid peroxidation, did not cor-
relate with Lp-PLA2 activity in the present study. This lack of
correlation may be partly explained by the low association be-
tween Lp-PLA2 and LDL cholesterol in the Korean population
(37), which has relatively low concentrations of LDL cholesterol
(115 mg/dL for middle-aged Koreans) and a high incidence of the
Val279Phe variant in the Lp-PLA2 gene, which indicates loss of
enzyme activity. The Val279Phe variant of Lp-PLA2 has been
reported to be associated with a lower risk of cardiovascular
disease in Korean men (37). However, this result may relate to
previous findings that Lp-PLA2 does not affect the lipid peroxi-
dation of LDL (38–40). In fact, this possibility is plausible,
because the main role of Lp-PLA2 in atherogenesis is the hydro-
lysis of ox-LDL, which is generated when LDL becomes oxi-
dized in the milieu of the artery wall (41).
MDA, another lipid peroxide, is widely used as an index of
oxidative damage because of its ability to interact with lipopro-
tein (13); however, plasma MDA measurement was reported to
be a less reliable assay than lymphocyte DNA damage for de-
tecting the severity of vascular lesions in CAD patients (42). In
the present study, the weak correlation observed between MDA
and Lp-PLA2 activity may reflect differences in specificity and
sensitivity for different lipid peroxides. Because the specificity
of the MDA assay is low, MDA is regarded as a general indicator
FIGURE 1. Association of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and urinary 8-epi-prostaglandin F2 (8-epi-PGF2) concentrations
with coronary artery disease. Odds ratios were adjusted for sex, age, BMI, systolic and diastolic blood pressure, and smoking and alcohol consumption status.
Lp-PLA2 activity  8-epi-PGF2 concentrations interactions were significant for coronary artery disease risk: *P  0.05, **P  0.01, and ***P  0.001.
Compared with persons in the lowest quartile of Lp-PLA2 activity (20.4 nmol  mL1  min1) and of 8-epi-PGF2 (744.6 pg/mg creatinine), persons in most
of the other categories had a significant association with a greater risk of coronary artery disease risk; those in the lowest quartile of Lp-PLA2 activity and the
second and third quartiles of 8-epi-PGF2 did not have a significantly greater risk.
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of oxidative stress rather than as a specific marker of lipid per-
oxidation (13, 43, 44).
We observed lower concentrations of total cholesterol, LDL
cholesterol, and ox-LDL in CAD patients, which reflected their
widespread use of statin therapy. Although statins can reduce
Lp-PLA2 activity (45), CRP concentrations (46), and oxidative
stress (47), we found that Lp-PLA2 activity, CRP, and urinary
excretion of 8-epi-PGF2 were higher in CAD cases than in
controls. Moreover, in these controls, CRP was positively cor-
related with urinary excretion concentrations of PGF2 (r 
0.134, P0.001) in the absence of correlation between Lp-PLA2
and CRP. This observation may indicate that inflammation is
closely associated with oxidative stress. Schwedhelm et al (19)
also found an association between CRP and urinary excretion
concentrations of 8-epi-PGF2, which was not confounded by
lipid-lowering therapy or by total cholesterol, LDL-cholesterol,
or triglyceride concentrations.
One limitation of the present study, as for all such case-control
studies in which exposure and outcome are collected at one
time-point, is the inability to assess the temporal sequence of the
described associations. Despite this limitation, our results show
an association of elevated Lp-PLA2 activity with a higher inci-
dence of CAD in relation to greater oxidant stress and thus sup-
port the hypothesis that Lp-PLA2 represents a novel, viable
marker for CAD risk.
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